Amgen Inc. (AMGN)
David Stone of Cowen & Co. reiterated a "strong buy" after ABTI's Betafectin results came under fire primarily because of the study design. While there aren't yet data from AMGN's infectious disease trials of Neupogen, the company has earned its stripes from the medical community on the